CN1301762A - New polypeptide-human lissencephalic protein 43 and polynucleotide coding such polypeptide - Google Patents

Abstract

The invention discloses a new polypeptide-human lissencephalic protein 43, polynucleotide encoding the polypeptide and a method for producing the polypeptide through DNA recombination technology. The invention also discloses a method for using the polypeptide to treat various diseases, such as malignant tumors, blood diseases, HIV infection, immune diseases and various inflammations. The invention also discloses an antagonist against the polypeptide and its therapeutic effect. The invention also discloses the application of the polynucleotide encoding the novel human lissencephaly protein 43.

Description

The polynucleotide of a kind of new polypeptide--people's congenital agyria protein 43 and this peptide species of coding

The invention belongs to biological technical field, specifically, the invention describes a kind of new polypeptide--people's congenital agyria protein 43, and the polynucleotide sequence of this polypeptide of encoding.The invention still further relates to the preparation method and the application of these polynucleotide and polypeptide.

The WD-40 tumor-necrosis factor glycoproteins is found from the proteic β of G subunit the earliest.The film of striding of the protein mediated signal of G conducts, it is made up of α, β, three subunits of γ, wherein alpha subunit can in conjunction with and hydrolysis GTP, the function of β, γ subunit is not too clear, but find their identification, play a crucial role in the process of grappling and GTP replacement GDP at membrane receptor.

In higher eucaryote, by the little gene family that the albumen of a plurality of high conservatives is formed, these proteinic length are about 340 amino acid in β subunit (being called for short G-β).Structurally, G-β tandemly contains 40 amino acid whose tumor-necrosis factor glycoproteinss and forms by 8.Each tumor-necrosis factor glycoproteins all contains a Trp-Asp Motif (also being called the WD-40 tumor-necrosis factor glycoproteins).

This conserved sequence is characterized as: (n1) LxGHxxxIxx Φ x δ (n2) Φ Φ SGGxDxx Φ xIWD δ F L TAA N C LFN

V S VY or: [LIVMSTAC]-[LIVMFYWSTAGC]-[LIMSTAG]-[LIVMSTAGC]-x (2)-[DN]-

x(2)-[LIVMWSTAC]-x-[LIVMFSTAG]-W-[DEN]-[LIVMFSTAGCN]

It is emphasized that the albumen that contains Trp-Asp Motif (WD-40 tumor-necrosis factor glycoproteins), its function is not quite similar, and is variation, and cellular localization also has nothing in common with each other, can be at karyon, and plasma membrane and cytoskeleton etc.Therefore gene function and the practical situation of inferring from this Motif differ bigger.

Polypeptide of the present invention and Miller-Dieker congenital agyria 1 type albumen homology (Miller-Diekerlissencephaly protein, LISl).Miller-Dieker congenital agyria 1 type albumen is cloned from people's tire brain the earliest, and its full length gene is 2750bp, 288 amino acid of encoding.Chromosomal localization 17p13.3.Show that on evidence this proteic disappearance damaged or karyomit(e) 17p13.3 can cause lissencephalous generation, the clinical Miller-Dieker syndromes that is referred to as.

Because gene and people's congenital agyria protein gene homology of code book invention polypeptide, infer that this albumen plays an important role in the growth of cortex, in conjunction with its Motif function, infer that further this gene in the signal conductive process, especially plays a significant role in the transmembrane signal conductive process.In Africa xenopus, be subjected to Triiodothyronine to raise this fact according to it with former albumen, infer that this albumen is subjected to hormone regulating and controlling, the function performance of mediation Triiodothyronine takes place unusual as this albumen, may show as the symptom of athyroxinosis disease clinically, as cretinism etc.As mentioned above, this gene may with congenital or posteriori encephalodysplasia, dementia or mental retardation have substantial connection.According to homology result relatively, polypeptide of the present invention is accredited as a kind of new people's congenital agyria albumen by deduction, and name is people's congenital agyria protein 43.

Because people's congenital agyria protein 43 albumen plays an important role in the body critical function as mentioned above, and believe and relate to a large amount of albumen in these regulate processes, thereby need to identify people's congenital agyria protein 43 albumen of more these processes of participation in this area always, particularly identify this proteic aminoacid sequence.The separation of new person's congenital agyria protein 43 protein coding gene also provides the foundation for determining the effect of this albumen under healthy and morbid state.This albumen may constitute the basis of exploitation medical diagnosis on disease and/or curative, and it is very important therefore separating its coding DNA.

An object of the present invention is to provide isolating new polypeptide--people's congenital agyria protein 43 with and fragment, analogue and derivative.

Another object of the present invention provides the polynucleotide of this polypeptide of coding.

Another object of the present invention provides the recombinant vectors of the polynucleotide that contain coding people congenital agyria protein 43.

Another object of the present invention provides the genetically engineered host cell of the polynucleotide that contain coding people congenital agyria protein 43.

Another object of the present invention provides the method for producing people's congenital agyria protein 43.

Another object of the present invention provides at polypeptide of the present invention--the antibody of people's congenital agyria protein 43.Another object of the present invention has provided at polypeptide of the present invention--simulated compound, antagonist, agonist, the inhibitor of people's congenital agyria protein 43.

Another object of the present invention provides the method for the diagnoses and treatment disease relevant unusually with people's congenital agyria protein 43.

The present invention relates to a kind of isolated polypeptide, this polypeptide is the people source, and it comprises: polypeptide or its examples of conservative variations, bioactive fragment or derivative with SEQ ID No.2 aminoacid sequence.Preferably, this polypeptide is the polypeptide with SEQ ID NO:2 aminoacid sequence.

The invention still further relates to a kind of isolating polynucleotide, it comprises a kind of nucleotide sequence or its variant that is selected from down group:

(a) coding has the polynucleotide of the polypeptide of SEQ ID No.2 aminoacid sequence;

(b) with polynucleotide (a) complementary polynucleotide;

(c) with (a) or polynucleotide sequence (b) have the polynucleotide of at least 70% homogeny.

More preferably, the sequence of these polynucleotide is be selected from down group a kind of: the sequence that (a) has 20-1198 position among the SEQ ID NO:1; (b) has the sequence of 1-1558 position among the SEQ ID NO:1.

The present invention relates to a kind of carrier that contains polynucleotide of the present invention, particularly expression vector in addition; The host cell that this carrier of a kind of usefulness is genetically engineered comprises the host cell of conversion, transduction or transfection; A kind of method for preparing polypeptide of the present invention of cultivating described host cell and reclaiming expression product that comprises.

The invention still further relates to a kind of can with polypeptid specificity bonded antibody of the present invention.

The invention still further relates to a kind of simulation, activation, antagonism of screening or suppress the method for the compound of people's congenital agyria protein 43 protein-active, it comprises and utilizes polypeptide of the present invention.The invention still further relates to the compound that obtains with this method.

The invention still further relates to a kind of vitro detection and express the relevant disease or the method for disease susceptibility with people's congenital agyria protein 43 abnormal protein, comprise the sudden change in polypeptide described in the detection of biological sample or its coded polynucleotide sequence, perhaps the amount or the biological activity of polypeptide of the present invention in the detection of biological sample.

The present invention also relates to a kind of pharmaceutical composition, it contains polypeptide of the present invention or its stand-in, activator, antagonist or inhibitor and pharmaceutically acceptable carrier.

The invention still further relates to polypeptide of the present invention and/or polynucleotide and be used for the treatment of cancer, developmental character disease or immunological disease or other purposes owing to the medicine of people's congenital agyria protein 43 disease that abnormal expression causes in preparation.

Others of the present invention are because disclosing of the technology of this paper is conspicuous to those skilled in the art.

The following term of using in this specification sheets and claims has following implication unless stated otherwise: " nucleotide sequence " is meant oligonucleotide, Nucleotide or polynucleotide and fragment or part, also can refer to genome or synthetic DNA or RNA, they can be strand or two strands, represent sense strand or antisense strand.Similarly, term " aminoacid sequence " is meant oligopeptides, peptide, polypeptide or protein sequence and fragment or part.When " aminoacid sequence " among the present invention related to a kind of aminoacid sequence of naturally occurring protein molecule, this " polypeptide " or " protein " did not mean that aminoacid sequence are restricted to the complete natural amino acid relevant with described protein molecule.

Protein or polynucleotide " variant " are meant a kind of polynucleotide sequence that has the aminoacid sequence of one or more amino acid or Nucleotide change or encode it.Described change can comprise disappearance, insertion or the replacement of amino acid in aminoacid sequence or the nucleotide sequence or Nucleotide.Variant can have " conservative property " and change, and wherein the amino acid of Ti Huaning has structure or the chemical property similar with original acid, as replacing Isoleucine with leucine.Variant also can have non-conservation and change, as replacing glycine with tryptophane.

" disappearance " is meant the disappearance of in aminoacid sequence or nucleotide sequence one or more amino acid or Nucleotide.

" insertion " or " interpolation " is meant that the change in aminoacid sequence or nucleotide sequence causes comparing the increase of one or more amino acid or Nucleotide with naturally occurring molecule." replacement " is meant by different amino acid or Nucleotide and replaces one or more amino acid or Nucleotide.

" biological activity " is meant the protein of structure, regulation and control or biochemical function with natural molecule.Similarly, term " immunologic competence " be meant natural, reorganization or synthetic protein and fragment thereof in suitable animal or cell, induce specific immune response and with specific antibody bonded ability.

" agonist " is meant when combining with people's congenital agyria protein 43, thereby a kind of this protein that causes changes the molecule of regulating this protein active.Agonist can comprise protein, nucleic acid, carbohydrate or any other can be in conjunction with the molecule of people's congenital agyria protein 43.

" antagonist " or " inhibition " is meant when combining with people's congenital agyria protein 43, a kind of sealing or the biologic activity of mediator's congenital agyria protein 43 or the molecule of immunologic competence.Antagonist and inhibition can comprise protein, nucleic acid, carbohydrate or any other can be in conjunction with the molecule of people's congenital agyria protein 43.

" adjusting " is meant that the function of people's congenital agyria protein 43 changes, and comprises the change of any other biological property, function or the immune property of the change of the rising of protein active or reduction, binding characteristic and people's congenital agyria protein 43.

The pure basically ＂ of ＂ is meant and is substantially free of natural relative other albumen, lipid, carbohydrate or other material.Those skilled in the art can use the purified technology of protein purifying people congenital agyria protein 43 of standard.Basically pure people's congenital agyria protein 43 can produce single master tape on the irreducibility polyacrylamide gel.The purity available amino end acid sequence of people's congenital agyria protein 43 polypeptide is analyzed.

" complementary " or " complementation " is meant under salt concn that allows and temperature condition by the natural combination of the polynucleotide of base pairing.For example, sequence " C-T-G-A " can combine with complementary sequence " G-A-C-T ".Complementation between two single chain molecules can be part or whole.Complementary degree between the nucleic acid chains has a significant effect for efficient of hybridizing between the nucleic acid chains and intensity.

" homology " is meant the complementary degree, can be portion homologous or complete homology." portion homologous " is meant a kind of part complementary sequence, and it can partly suppress the hybridization of complete complementary sequence and target nucleic acid at least.The inhibition of this hybridization can detect by hybridizing (Southern trace or Northern trace etc.) under the condition that reduces in the severity degree.Basically homologous sequence or hybridization probe can compete and suppress complete homologous sequence and target sequence the condition that reduces of severity degree under combine.This does not mean the conditions permit non-specific binding that the severity degree reduces because the conditional request two sequences that the severity degree reduces mutual be combined into specificity or selectivity interacts.

" homogeny percentage " be meant two or more amino acid or nucleotide sequence relatively in the same or analogous percentage of sequence.The available electron method is measured the homogeny percentage, as passing through MEGALIGN program (Lasergene softwarepackage, DNASTAR, Inc., Madison Wis.).The MEGALIGN program can compare two or more sequences (Higgins, D.G. and P.M.Sharp (1988) Gene 73:237-244) according to diverse ways such as Cluster method.The Cluster method is organized the series arrangement cluster by checking the distance between all pairings with each.Then with each bunch with in pairs or become set of dispense.Homogeny percentage between two aminoacid sequences such as sequence A and the sequence B calculates by following formula:

The residue number of mating between sequence A and the sequence B

100 (in the residue number-sequence A of sequence A at interval in residue number-sequence B residue number) at interval

Also can be by the Cluster method or with the homogeny percentage (Hein J., (1990) Methods in emzumology 183:625-645) between known method in this area such as the Jotun Hein mensuration nucleotide sequence.

" similarity " is meant the degree that the identical or conservative property of corresponding position amino-acid residue when arranging contrast between the aminoacid sequence replaces.For example be used for amino acid that conservative property replaces, electronegative amino acid can comprise aspartic acid and L-glutamic acid; Positively charged amino acid can comprise Methionin and arginine; Having uncharged head group has similar hydrophilic amino acid can comprise leucine, Isoleucine and Xie Ansuan; Glycine and L-Ala; L-asparagine and glutamine; Serine and Threonine; Phenylalanine and tyrosine.

" antisense " is meant and specific DNA or RNA sequence complementary nucleotide sequence." antisense strand " is meant and " sense strand " complementary nucleic acid chains.

" derivative " is meant HFP or encodes its chemical modification object of nucleic acid.This chemical modification object can be with alkyl, acyl group or the amino hydrogen atom of replacing.The nucleic acid derivative codified keeps the polypeptide of the main biological characteristics of natural molecule.

" antibody " is meant complete antibody molecule and fragment thereof, as Fa, F (ab ') ₂And Fv, its energy specificity is in conjunction with the antigenic determinant of people's congenital agyria protein 43.

" humanized antibody " is meant that the aminoacid sequence in non-antigen binding domain territory is replaced and becomes more similar to people's antibody, but still keep original in active antibody.

" isolating " speech refers to material is shifted out among its original environment (for example, if spontaneous its natural surroundings that just refers to).Such as it is exactly not to be separated that spontaneous polynucleotide or polypeptide are present in the Live Animals, but same polynucleotide or polypeptide with some or all in natural system with it the material of coexistence separately be exactly isolating.Such polynucleotide may be the parts of a certain carrier, the part that also possible such polynucleotide or polypeptide are a certain composition.Since carrier or composition are not the compositions of its natural surroundings, they remain isolating.

As used herein, " isolating " are meant that material separates (if natural substance, primal environment promptly is a natural surroundings) from its primal environment.Do not have separation and purification as polynucleotide under the native state in the active somatic cell and polypeptide, but same polynucleotide or polypeptide as from native state with in other materials that exist separately, then for separation and purification.

As used herein, " isolating people's congenital agyria protein 43 " is meant that people's congenital agyria protein 43 does not conform to natural relative other albumen, lipid, carbohydrate or other material basically.Those skilled in the art can use the purified technology of protein purifying people congenital agyria protein 43 of standard.Basically pure polypeptide can produce single master tape on non-reduced polyacrylamide gel.The purity of people's congenital agyria protein 43 polypeptide can be used amino acid sequence analysis.

The invention provides a kind of new polypeptide--people's congenital agyria protein 43, it is made up of the aminoacid sequence shown in the SEQ IDNO:2 basically.Polypeptide of the present invention can be recombinant polypeptide, natural polypeptides, synthetic polypeptide, preferred recombinant polypeptide.Polypeptide of the present invention can be the product of natural purifying, or the product of chemosynthesis, or uses recombinant technology to produce from protokaryon or eucaryon host (for example, bacterium, yeast, higher plant, insect and mammalian cell).The host used according to the recombinant production scheme, polypeptide of the present invention can be glycosylated, maybe can be nonglycosylated.Polypeptide of the present invention also can comprise or not comprise initial methionine residues.The present invention also comprises fragment, derivative and the analogue of people's congenital agyria protein 43.As used herein, term " fragment ", " derivative " are meant biological function or the active polypeptide that keeps people's congenital agyria protein 43 of the present invention identical basically with " analogue ".The fragment of polypeptide of the present invention, derivative or analogue can be: (I) is a kind of like this, wherein one or more amino-acid residues are replaced by conservative or non-conservative amino acid residues (preferably conservative amino acid residues), and the amino acid that replaces can be also can not encoded by genetic codon; Perhaps (II) is a kind of like this, and certain group on wherein one or more amino-acid residues is replaced by other group and comprises substituting group; Perhaps (III) is a kind of like this, and wherein mature polypeptide and another kind of compound (such as the compound that prolongs the polypeptide transformation period, for example polyoxyethylene glycol) merge; Perhaps (IV) is a kind of like this, wherein additional aminoacid sequence is integrated into mature polypeptide and the peptide sequence that forms (as leader sequence or secretion sequence or be used for the sequence or the proteinogen sequence of this polypeptide of purifying) by the elaboration of this paper, such fragment, derivative and analogue are considered within those skilled in the art's ken.

The invention provides isolating nucleic acid (polynucleotide), substantially the polynucleotide that have a polypeptide of SEQ ID NO:2 aminoacid sequence by coding are formed.Polynucleotide sequence of the present invention comprises the nucleotide sequence of SEQ ID NO:1.Polynucleotide of the present invention are to find from the cDNA library of people's fetal brain tissue.The polynucleotide sequence total length that it comprises is 1558 bases, its open reading frame (20-1198) 392 amino acid of having encoded.This polypeptide has the characteristic sequence of WD-40 tumor-necrosis factor glycoproteins, and deducibility goes out the 26S Proteasome Structure and Function that this people's congenital agyria protein 43 has WD-40 tumor-necrosis factor glycoproteins representative.

Polynucleotide of the present invention can be dna form or rna form.Dna form comprises the DNA of cDNA, genomic dna or synthetic.DNA can be strand or double-stranded.DNA can be coding strand or noncoding strand.The coding region sequence of encoding mature polypeptide can be identical with the coding region sequence shown in the SEQ ID NO:1 or the varient of degeneracy.As used herein, " varient of degeneracy " are meant that in the present invention coding has protein or the polypeptide of SEQ ID NO:2, but with the differentiated nucleotide sequence of coding region sequence shown in the SEQ ID NO:1.

The polynucleotide of the mature polypeptide of coding SEQ ID NO:2 comprise: the encoding sequence that has only mature polypeptide; The encoding sequence of mature polypeptide and various additional code sequence; Encoding sequence of mature polypeptide (with optional additional code sequence) and non-coding sequence.

Term " polynucleotide of coded polypeptide " is meant polynucleotide that comprise this polypeptide of encoding and the polynucleotide that comprise additional code and/or non-coding sequence.

The invention still further relates to the varient of foregoing description polynucleotide, its coding has the polypeptide of identical aminoacid sequence or segment, analogue and the derivative of polypeptide with the present invention.The varient of these polynucleotide can be the allelic variant of natural generation or the varient that non-natural takes place.These nucleotide diversity bodies comprise and replace varient, deletion mutation body and insert varient.As known in the art, allelic variant is the replacement form of polynucleotide, and it may be replacement, disappearance or the insertion of one or more Nucleotide, but can be from not changing the function of its encoded polypeptides in fact.

The invention still further relates to and the polynucleotide (have at least 50% between two sequences, preferably have 70% homogeny) of sequence hybridization described above.The present invention be more particularly directed under stringent condition and the interfertile polynucleotide of polynucleotide of the present invention.In the present invention, " stringent condition " is meant: (1) than hybridization under low ionic strength and the comparatively high temps and wash-out, as 0.2 * SSC, and 0.1%SDS, 60 ℃; Or (2) hybridization the time adds and to use denaturing agent, as 50% (v/v) methane amide, 0.1% calf serum/0.1%Ficoll, 42 ℃ etc.; Or (3) only at the homogeny between the two sequences at least more than 95%, be more preferably 97% and just hybridize when above.And the polypeptide of interfertile polynucleotide encoding has identical biological function and activity with the mature polypeptide shown in the SEQ ID NO:2.

The invention still further relates to nucleic acid fragment with sequence hybridization described above.As used herein, " nucleic acid fragment " length contain 10 Nucleotide at least, better be 20-30 Nucleotide at least, be more preferably 50-60 Nucleotide at least, preferably more than at least 100 Nucleotide.Nucleic acid fragment also can be used for the amplification technique (as PCR) of nucleic acid to determine and/or to separate the polynucleotide of coding people congenital agyria protein 43.

Polypeptide among the present invention and polynucleotide preferably provide with isolating form, more preferably are purified to homogeneous.

The special polynucleotide sequence of coding people congenital agyria protein 43 of the present invention can obtain with several different methods.For example, separate polynucleotide with hybridization technique well known in the art.These technology including, but not limited to: 1) with probe and genome or the hybridization of cDNA library to detect homologous polynucleotide sequence and 2) antibody screening of expression library to be to detect the polynucleotide passage of the clone with common structure feature.

Sequence dna fragment of the present invention also can obtain with following method: 1) separate double chain DNA sequence from genomic dna; 2) the chemical synthesising DNA sequence is to obtain the double-stranded DNA of described polypeptide.

In the above-mentioned method of mentioning, isolation of genomic DNA is least commonly used.The direct chemical of dna sequence dna is synthetic to be the method for often selecting for use.The more frequent method of selecting for use is the separation of cDNA sequence.The standard method that separates interested cDNA is from the donorcells separating mRNA of this gene of high expression level and carries out reverse transcription, forms plasmid or phage cDNA library.Extract the existing multiple proven technique of method of mRNA, test kit also can obtain (Qiagene) from commercial channels.And the construction cDNA library also is usual method (Sambrook, et al., MolecularCloning, A Laboratory Manual, Cold Spring Harbor Laboratory.New York, 1989).Also can obtain the cDNA library of commercial offers, as the different cDNA library of Clontech company.When being used in combination the polymeric enzyme reaction technology, even few expression product also can be cloned.

Available ordinary method is screened gene of the present invention from these cDNA libraries.These methods include, but is not limited to: (1) DNA-DNA or DNA-RNA hybridization; (2) appearance of marker gene function or forfeiture; (3) level of the transcript of mensuration people congenital agyria protein 43; (4), detect the protein product of genetic expression by immunological technique or mensuration biologic activity.Aforesaid method can singly be used, but also several different methods combined utilization.

In (1) kind method, hybridizing used probe is and any a part of homology of polynucleotide of the present invention that at least 10 Nucleotide of its length better are at least 30 Nucleotide, are more preferably at least 50 Nucleotide, preferably at least 100 Nucleotide.In addition, within 2000 Nucleotide, preferable is within 1000 Nucleotide to the length of probe usually.Probe used herein is the dna sequence dna of chemosynthesis on the basis of gene order information of the present invention normally.Gene of the present invention itself or fragment are certainly as probe.The mark of dna probe can be used radio isotope, fluorescein or enzyme (as alkaline phosphatase) etc.

In (4) kind method, detect the protein product of people's congenital agyria protein 43 genetic expression and can use immunological technique such as Western blotting, radioimmunoprecipitation, enzyme-linked immunosorbent assay (ELISA) etc.

Use method (Saiki, the et al.Science1985 of round pcr DNA amplification/RNA; 230:1350-1354) be optimized for acquisition gene of the present invention.When particularly being difficult to from the library, obtain the cDNA of total length, can preferably use RACE method (the terminal rapid amplifying method of RACE-cDNA), the primer that is used for PCR can suitably be selected according to polynucleotide sequence information of the present invention disclosed herein, and available ordinary method is synthetic.Available ordinary method is as the DNA/RNA fragment by gel electrophoresis separation and purifying amplification.

The gene of the present invention that obtains as mentioned above, perhaps the polynucleotide sequence of various dna fragmentations etc. can with ordinary method such as dideoxy chain termination (Sanger et al.PNAS, 1977,74:5463-5467) measure.This class polynucleotide sequence is measured also available commercial sequencing kit etc.In order to obtain the cDNA sequence of total length, order-checking need be carried out repeatedly.Sometimes need to measure a plurality of clones' cDNA sequence, just can be spliced into the cDNA sequence of total length.

The present invention also relates to comprise the carrier of polynucleotide of the present invention, and the host cell that produces through genetically engineered with the carrier of the present invention or the congenital agyria protein 43 encoding sequence of directly choosing, and the method that produces polypeptide of the present invention through recombinant technology.

Among the present invention, the polynucleotide sequence of coding people congenital agyria protein 43 can be inserted in the carrier, contains the recombinant vectors of polynucleotide of the present invention with formation.Term " carrier " refers to that bacterial plasmid well known in the art, phage, yeast plasmid, vegetable cell virus, mammalian cell virus are as adenovirus, retrovirus or other carrier.The carrier of Shi Yonging includes but not limited in the present invention: and the expression vector based on the T7 promotor of in bacterium, expressing (Rosenberg, et al.Gene, 1987,56:125); The pMSXND expression vector of in mammalian cell, expressing (Lee and Nathans, J Bio Chem.263:3521,1988) and at the carrier that derives from baculovirus of expressed in insect cells.In a word, as long as can duplicate in host and stablize, any plasmid and carrier may be used to make up recombinant expression vector.A key character of expression vector is to contain replication origin, promotor, marker gene and translational control element usually.

Method well-known to those having ordinary skill in the art can be used to make up the dna sequence dna that contains coding people congenital agyria protein 43 and the expression vector of suitable transcribing/translational control element.These methods comprise (Sambroook, et al.Molecular Cloning, aLaboratory Manual, cold Spring Harbor Laboratory.New York, 1989) such as extracorporeal recombinant DNA technology, DNA synthetic technology, the interior recombinant technologys of body.Described dna sequence dna can effectively be connected on the suitable promotor in the expression vector, and is synthetic to instruct mRNA.The representative example of these promotors has: colibacillary lac or trp promotor; The PL promotor of lambda particles phage; Eukaryotic promoter comprises LTRs and some other known may command gene expression promoter in prokaryotic cell prokaryocyte or eukaryotic cell or its virus of CMV immediate early promoter, HSV thymidine kinase promoter, early stage and late period SV40 promotor, retrovirus.Expression vector also comprises ribosome bind site that translation initiation is used and transcription terminator etc.Inserting enhancer sequence in carrier will make its transcribing in higher eucaryotic cells be enhanced.Enhanser is the cis acting factor that DNA expresses, and nearly 10 to 300 base pairs act on promotor transcribing with enhancing gene usually.Can for example be included in the SV40 enhanser of 100 to 270 base pairs of replication origin side in late period one, at the polyoma enhanser of replication origin side in late period one and adenovirus enhanser etc.

In addition, expression vector preferably comprises one or more selected markers, to be provided for selecting the phenotypic character of transformed host cells, cultivate Tetrahydrofolate dehydrogenase, neomycin resistance and the green fluorescent protein (GFP) of usefulness as eukaryotic cell, or be used for colibacillary tsiklomitsin or amicillin resistance etc.

Persons skilled in the art all know how to select appropriate carriers/transcriptional regulatory element (as promotor, enhanser etc.) and selected marker.

Among the present invention, the polynucleotide of coding people congenital agyria protein 43 or the recombinant vectors that contains these polynucleotide can transform or transduce into host cell, contain the genetically engineered host cell of these polynucleotide or recombinant vectors with formation.Term " host cell " refers to prokaryotic cell prokaryocyte, as bacterial cell; Or eukaryotic cell such as low, as yeast cell; Or higher eucaryotic cells, as mammalian cell.Representative example has: intestinal bacteria, streptomyces; Bacterial cell such as Salmonella typhimurium; Fungal cell such as yeast; Vegetable cell; Insect cell such as fruit bat S2 or Sf9; Zooblast such as CHO, COS or Bowes melanoma cells etc.

Can carry out with routine techniques well known to those skilled in the art with dna sequence dna of the present invention or the recombinant vectors transformed host cell that contains described dna sequence dna.When the host was prokaryotic organism such as intestinal bacteria, the competent cell that can absorb DNA can be used CaCl in exponential growth after date results ₂Method is handled, and used step is well-known in this area.Alternative is to use MgCl ₂If desired, transforming also the method for available electroporation carries out.When the host is an eukaryote, can select following DNA transfection method for use: coprecipitation of calcium phosphate method, perhaps conventional mechanical method such as microinjection, electroporation, liposome packing etc.

By the recombinant DNA technology of routine, utilize polynucleotide sequence of the present invention to can be used to express or produce people's congenital agyria protein 43 (Science, 1984 of reorganization; 224:1431).In general following steps are arranged:

(1). with the polynucleotide (or varient) of everybody congenital agyria protein 43 of coding of the present invention, or transform or the transduction proper host cell with the recombinant expression vector that contains these polynucleotide;

(2). in suitable medium, cultivate host cell;

(3). separation, protein purification from substratum or cell.

In step (2), according to used host cell, used substratum can be selected from various conventional substratum in the cultivation.Under the condition that is suitable for the host cell growth, cultivate.After host cell grows into suitable cell density, induce the promotor of selection with suitable method (as temperature transition or chemical induction), cell is cultivated for some time again.

In step (3), recombinant polypeptide can wrap and be expressed or be secreted into the extracellular in cell or on cytolemma.If desired, can utilize its physics, the separating by various separation methods with other characteristic and the albumen of purification of Recombinant of chemistry.These methods are well-known to those skilled in the art.These methods include, but are not limited to: conventional renaturation is handled, protein precipitant is handled (salt analysis method), centrifugal, the broken bacterium of infiltration, the combination of ultrasonication, super centrifugal, sieve chromatography (gel-filtration), adsorption chromatography, ion exchange chromatography, high performance liquid chromatography (HPLC) and other various liquid chromatography (LC) technology and these methods.

The antagonist of polypeptide of the present invention and this polypeptide, agonist and inhibitor can be directly used in disease treatment, for example, can treat malignant tumour, adrenal gland defect, tetter, all kinds of inflammation, HIV infection and immunological disease etc.

The WD-40 tumor-necrosis factor glycoproteins is found from the proteic β of G subunit the earliest.The film of striding of the protein mediated signal of G conducts, it is made up of α, β, three subunits of γ, a little gene family being made up of the albumen of a plurality of high conservatives of β subunit (be called for short G-β) wherein, G-β have special Trp-Asp Motif (also being called the WD-40 tumor-necrosis factor glycoproteins) and form that it is active essential.Contain the albumen of Trp-Asp Motif (WD-40 tumor-necrosis factor glycoproteins), its function is not quite similar, and is variation, and cellular localization also has nothing in common with each other, can be at karyon, and plasma membrane and cytoskeleton etc.

Discover polypeptide and the Miller-Dieker congenital agyria 1 type albumen homology that contains Trp-Asp Motif of the present invention.It may be regulated and control by Triiodothyronine, and the function performance of mediation Triiodothyronine takes place unusually as this albumen, may show as the symptom of athyroxinosis disease clinically, as cretinism etc.

This shows, the dysfunction that contains the polypeptide of this motif of the present invention, thereby what cause the protein mediated signal of G strides the unusual of film conduction function, and may produce unusual in the fetal development stage, or make body be subjected to Triiodothyronine regulation and control unusual, and produce relevant disease such as fetal development disorder, Triiodothyronine is regulated and control unusual relative disease, tumour, dysplasia etc.

This shows that the abnormal expression of people's congenital agyria protein 43 of the present invention will produce especially fetal development disorder of various diseases, Triiodothyronine is regulated and control unusual relative disease, tumour, dysplasia, these diseases include but not limited to:

Fetal development disorders: congenital miscarriage, cleft palate, deficiency of skeletal limb, limbs dysdifferentiation, hyaline membrane disease, atelectasis, polycystic kidney, double ureter, cryptorchidism, congenital inguinal hernia, duplex uterus, vaginal atresia, hypospadia, hermaphroditism, atrial septal defect, ventricular septal defect, pulmonic stenosis, patent ductus arteriosus, neural tube defect, congenital hydrocephalus, iridocoloboma, congenital cataract, congenital glaucoma or cataract, congenital deafness

Triiodothyronine is regulated and control unusual relative disease: simple goiter, thyroiditis, hyperthyroidism, hypothyroidism, cretinism

Dysplasia disease: mental retardation, cerebral plasy, cerebral dysgenesis, dysnoesia, familial nuclei of cranial nerves underdevelopment syndromes, stravismus, skin, fat and amyoplasia disease such as congenital cutis laxa, senium praecox, congenital dyskeratosis, various metabolic defects such as various amino acid metabolism defective disease, cretinism, nanism, the slow disease of sexual development

The tumour of various tissues: cancer of the stomach, liver cancer, lung cancer, the esophageal carcinoma, mammary cancer, leukemia, lymphoma, thyroid tumor, hysteromyoma, neuroblastoma, astrocytoma, ependymoma, glioma, colorectal carcinoma, melanoma, adrenal carcinoma, bladder cancer, osteocarcinoma, osteosarcoma, myelomatosis, bone marrow cancer, the cancer of the brain, uterus carcinoma, carcinoma of endometrium, carcinoma of gallbladder, colorectal carcinoma, thymus neoplasms, nasal cavity and tumor of sinus of nose, nasopharyngeal carcinoma, laryngocarcinoma, tracheal neoplasm, fibroma, fibrosarcoma, lipoma, liposarcoma, leiomyoma

The abnormal expression of people's congenital agyria protein 43 of the present invention also will produce some heredity, blood disease and disease of immune system etc.

The antagonist of polypeptide of the present invention and this polypeptide, agonist and inhibitor can be directly used in disease treatment, for example, can treat especially fetal development disorder of various diseases, Triiodothyronine is regulated and control unusual relative disease, tumour, dysplasia, some heredity, blood disease and disease of immune system etc.

The present invention also provides SCREENED COMPOUND to identify the method that improves (agonist) or check the medicament of (antagonist) people congenital agyria protein 43.Agonist improves people's congenital agyria protein 43 biological function such as stimulate cellular proliferation, and antagonist prevention disorder such as the various cancer relevant with cell hyperproliferation with treatment.For example, can in the presence of medicine, the film preparation of mammalian cell or expressing human congenital agyria protein 43 be cultivated with people's congenital agyria protein 43 of mark.Measure the medicine raising then or check this interactional ability.

The antagonist of people's congenital agyria protein 43 comprises antibody, compound, acceptor disappearance thing and the analogue etc. that filter out.The antagonist of people's congenital agyria protein 43 can combine and eliminate its function with people's congenital agyria protein 43, or suppresses the generation of this polypeptide, or combines with the avtive spot of this polypeptide and to make this polypeptide can not bring into play biological function.

In screening during as the compound of antagonist, people's congenital agyria protein 43 can be added during bioanalysis measures, determine to interactional influence between people's congenital agyria protein 43 and its acceptor whether compound is antagonist by measuring compound.With the same quadrat method of above-mentioned SCREENED COMPOUND, can filter out the acceptor disappearance thing and the analogue of antagonist action.Can be incorporated into the rondom polypeptide storehouse that solid formation forms by the various amino acid that may make up by screening with people's congenital agyria protein 43 bonded peptide molecule obtains.During screening, generally tackle people's congenital agyria protein 43 molecule and carry out mark.

The invention provides and use polypeptide, and fragment, derivative, analogue or their cell are as the method for antigen with production antibody.These antibody can be polyclonal antibody or monoclonal antibody.The present invention also provides the antibody at people's congenital agyria protein 43 antigenic determinant.These antibody include, but is not limited to: the fragment that polyclonal antibody, monoclonal antibody, chimeric antibody, single-chain antibody, Fab fragment and Fab expression library produce.

Can the choose method of congenital agyria protein 43 direct injection immune animal (as rabbit, mouse, rat etc.) of the production of polyclonal antibody obtains, and multiple adjuvant can be used for the enhancing immunity reaction, includes but not limited to freund's adjuvant etc.The technology of the monoclonal antibody of preparation people congenital agyria protein 43 include but not limited to hybridoma technology (Kohler and Milstein.Nature, 1975,256:495-497), three knurl technology, people B-quadroma technology, EBV-hybridoma technology etc.With the variable region bonded chimeric antibody in human constant region and inhuman source can with existing technology production (Morrison et al, PNAS, 1985,81:6851).And the technology of existing manufacture order chain antibody (U.S.Pat No.4946778) also can be used for producing the single-chain antibody of anti-people's congenital agyria protein 43.

The antibody of anti-people's congenital agyria protein 43 can be used in the immunohistochemistry technology, detects the people's congenital agyria protein 43 in the biopsy specimen.

With the also available labelled with radioisotope of people's congenital agyria protein 43 bonded monoclonal antibody, inject in the body and can follow the tracks of its position and distribution.This radiolabeled antibody can be used as a kind of atraumatic diagnostic method and is used for the location of tumour cell and has judged whether transfer.

Antibody also can be used for designing the immunotoxin at a certain privileged sites in the body.As the monoclonal antibody of people's congenital agyria protein 43 high-affinity can with bacterium or plant poison (as diphtheria toxin, ricin, abrine etc.) covalent attachment.A kind of usual method is with sulfydryl linking agent such as SPDP, attacks the amino of antibody, by the exchange of disulfide linkage, toxin is incorporated on the antibody, and this hybrid antibody can be used for killing people's congenital agyria protein 43 positive cells.

Antibody among the present invention can be used for treating or prevention and the relevant disease of people's congenital agyria protein 43.The antibody that gives suitable dosage can stimulate or block the generation or the activity of people's congenital agyria protein 43.

The invention still further relates to the diagnostic testing process of quantitative and detection and localization people congenital agyria protein 43 level.These tests are known in the art, and comprise that FISH measures and radioimmunoassay.The people's congenital agyria protein 43 level that is detected in the test can be with laying down a definition the importance of people's congenital agyria protein 43 in various diseases and be used to the disease of diagnosing people's congenital agyria protein 43 to work.

Polypeptide of the present invention also can be used as the peptide spectrum analysis, for example, the polypeptide available physical, chemistry or enzyme carry out the specificity cutting, and carries out the two-dimentional or three-dimensional gel electrophoresis analysis of one dimension, be more preferably and carry out mass spectroscopy.

The polynucleotide of coding people congenital agyria protein 43 also can be used for multiple therapeutic purpose.Gene therapy technology can be used for treating because cell proliferation, growth or the metabolic disturbance due to the nothing expression of people's congenital agyria protein 43 or the unusual/non-activity expression.The gene therapy vector (as virus vector) of reorganization can be designed for people's congenital agyria protein 43 of expressing variation, to suppress endogenic people's congenital agyria protein 43 activity.For example, a kind of people's congenital agyria protein 43 of variation can be the people's congenital agyria protein 43 that shortens, lacked signal conduction function territory, though can combine with the substrate in downstream, lacks signaling activity.Therefore the gene therapy vector of reorganization can be used for treating the disease of expression of people's congenital agyria protein 43 or active caused by abnormal.Deriving from viral expression vector such as retrovirus, adenovirus, adeno-associated virus (AAV), hsv, parvovirus etc. can be used for the polynucleotide of coding people congenital agyria protein 43 are transferred in the cell.The method of recombinant viral vector that structure carries the polynucleotide of coding people congenital agyria protein 43 is found in existing document (Sambrook, et al.).The polynucleotide of reorganization coding people congenital agyria protein 43 can be packaged in the liposome and be transferred in the cell in addition.

Polynucleotide import tissue or intracellular method comprises: directly be injected into polynucleotide in the in-vivo tissue; Or external by carrier (as virus, phage or plasmid etc.) earlier with the polynucleotide transfered cell in, again cell is transplanted in the body etc.

Suppress the oligonucleotide (comprising sense-rna and DNA) of people's congenital agyria protein 43 mRNA and ribozyme also within the scope of the invention.Ribozyme is the enzyme sample RNA molecule that a kind of energy specificity is decomposed specific RNA, and its mechanism of action is to carry out the endonuclease effect after ribozyme molecule and the hybridization of complementary target RNA-specific.The RNA of antisense and DNA and ribozyme can obtain with existing any RNA or DNA synthetic technology, as the technology widespread use of solid phase phosphoamide chemical synthesis synthetic oligonucleotide.Antisense rna molecule can be transcribed acquisition by the dna sequence dna of this RNA that encodes in external or body.This dna sequence dna has been incorporated into the downstream of rna polymerase promoter of carrier.In order to increase the stability of nucleic acid molecule, available several different methods is modified it, and as increasing the sequence length of both sides, the connection between the ribonucleoside is used phosphoric acid thioester bond or peptide bond but not phosphodiester bond.

The polynucleotide of coding people congenital agyria protein 43 can be used for the diagnosis with the relative disease of people's congenital agyria protein 43.The unconventionality expression of the expression that the polynucleotide of coding people congenital agyria protein 43 can be used for detecting people's congenital agyria protein 43 people's congenital agyria protein 43 whether or under morbid state.As the dna sequence dna of people's congenital agyria protein 43 of encoding can be used for biopsy specimen is hybridized to judge the expression situation of people's congenital agyria protein 43.Hybridization technique comprises the Southern blotting, Northern blotting, in situ hybridization etc.These technological methods all are disclosed mature technologies, and relevant test kit all can obtain from commercial channels.Part or all of polynucleotide of the present invention can be used as probe stationary on microarray (Microarray) or DNA chip (being called " gene chip " again), is used for analyzing the differential expression analysis and the gene diagnosis of tissue gene.The special primer of personnel selection congenital agyria protein 43 carries out the transcription product that RNA-polymerase chain reaction (RT-PCR) amplification in vitro also can detect people's congenital agyria protein 43.

The sudden change that detects people's congenital agyria protein 43 gene also can be used for the disease of diagnosing people's congenital agyria protein 43 relevant.The form of people's congenital agyria protein 43 sudden change comprises that the point mutation compared with normal wild type people congenital agyria protein 43 dna sequence dna, transposition, disappearance, reorganization and other are any unusual etc.Available existing technology such as Southern blotting, dna sequence analysis, PCR and in situ hybridization detect sudden change.In addition, sudden change might influence proteic expression, therefore can judge indirectly that with Northern blotting, Western blotting gene has or not sudden change.

Sequence of the present invention identifies it also is valuable to karyomit(e).This sequence can be specifically at certain bar human chromosome particular location and and can with its hybridization.At present, need to identify the concrete site of each gene on the karyomit(e).Now, have only chromosomal marker thing seldom to can be used for the marker chromosomes position based on actual sequence data (repetition polymorphism).According to the present invention, for these sequences are associated with disease related gene, its important the first step is positioned these dna sequence dnas on the karyomit(e) exactly.

In brief, prepare PCR primer (preferred 15-35bp), sequence can be positioned on the karyomit(e) according to cDNA.Then, these primers are used for the somatocyte hybrid cell that the PCR screening contains each bar human chromosome.Have only those hybrid cells that contain corresponding to the people's gene of primer can produce the fragment of amplification.

The PCR localization method of somatocyte hybrid cell is that DNA is navigated to concrete chromosomal quick method.Use Oligonucleolide primers of the present invention,, can utilize one group to realize inferior location from specific chromosomal fragment or a large amount of genomic clone by similar approach.Other the similar strategy that can be used for chromosomal localization comprises in situ hybridization, uses the karyomit(e) prescreen and the hybridization preliminary election of the airflow classification of mark, thereby makes up the special cDNA storehouse of karyomit(e).

The cDNA clone is carried out fluorescence in situ hybridization (FISH) with Metaphase Chromosome, can in a step, accurately carry out chromosomal localization.The summary of this technology is referring to Verma etc., Human Chromosomes:a Manualof Basic Techniques, Pergamon Press, New York (1988).

In case sequence is positioned to chromosome position accurately, the physical location of this sequence on karyomit(e) just can be associated with the gene map data.These data for example are found in, V.Mckusick, MendelianInheritance in Man (can by with the online acquisition of Johns Hopkins University Welch Medical Library).Can pass through linkage analysis then, determine gene and navigated to relation between the disease on the chromosomal region already.

Then, need to measure ill and not cDNA between diseased individuals or genome sequence difference.If observe certain sudden change in some or all of diseased individuals, and this sudden change is not observed in any normal individual, then this sudden change may be the cause of disease of disease.More ill and diseased individuals not is usually directed at first seek the variation of structure in the karyomit(e), as from the horizontal visible of karyomit(e) or use based on detectable disappearance of the PCR of cDNA sequence or transposition.Resolving power according to present physical mapping and assignment of genes gene mapping technology, being accurately positioned to the cDNA of the chromosomal region relevant with disease, can be a kind of (the supposing that 1 megabasse mapping resolving power and every 20kb are corresponding to a gene) between 50 to 500 potential Disease-causing genes.

Polypeptide of the present invention, polynucleotide and stand-in thereof, agonist, antagonist and inhibitor and suitable pharmaceutical carrier combination back can be used.These carriers can be water, glucose, ethanol, salt, damping fluid, glycerine and their combination.Composition comprises the polypeptide or the antagonist of safe and effective amount and carrier and the vehicle that does not influence effect of drugs.These compositions can be used as medicine and are used for disease treatment.

The present invention also provides medicine box or the test kit that contains one or more containers, and one or more medicinal compositions compositions of the present invention are housed in the container.With these containers, can have by the given indicative prompting of government authorities of making, using or selling medicine or biological products, the government authorities that this prompting reflects production, uses or sells permits it to use on human body.In addition, polypeptide of the present invention can be used in combination with other treatment compound.

Pharmaceutical composition can be with mode administration easily, as by in part, intravenously, intraperitoneal, intramuscular, subcutaneous, the nose or the route of administration of intracutaneous.People's congenital agyria protein 43 comes administration with the amount that treats and/or prevents concrete indication effectively.The amount and the dosage range that are applied to people's congenital agyria protein 43 of patient will depend on many factors, as administering mode, person's to be treated healthiness condition and diagnostician's judgement.

Following accompanying drawing is used to illustrate specific embodiments of the present invention, and is not used in qualification by the scope of the invention that claims defined.

Fig. 1 is inventor's congenital agyria protein 43 at the 180-228 amino acid sequence homology comparison diagram of totally 48 amino acid and structural domain WD-40 tumor-necrosis factor glycoproteins.The top sequence is people's congenital agyria protein 43, and the below sequence is a structural domain WD-40 tumor-necrosis factor glycoproteins.Same amino acid represents with monocase amino acid that between two sequences similar amino acid is represented with "+".

Fig. 2 is the polyacrylamide gel electrophoresis figure (SDS-PAGE) of isolating people's congenital agyria protein 43.43kDa is proteinic molecular weight.The arrow indication is isolated protein band.

Below in conjunction with specific embodiment, further set forth the present invention.Should be understood that these embodiment only to be used to the present invention is described and be not used in and limit the scope of the invention.The experimental technique of unreceipted actual conditions in the following example, usually according to people such as normal condition such as Sambrook, molecular cloning: laboratory manual (New York:Cold SpringHarbor Laboratory Press, 1989) condition described in, or the condition of advising according to manufacturer.Embodiment 1: the clone of people's congenital agyria protein 43

Extract the total RNA of people's tire brain with guanidinium isothiocyanate/phenol/chloroform single stage method.From total RNA, separate poly (A) mRNA with Quik mRNA Isolation Kit (Qiegene company product).2ug poly (A) mRNA forms cDNA through reverse transcription.CDNA fragment orientation is inserted on the multiple clone site of pBSK (+) carrier (Clontech company product) with Smart cDNA clone's test kit (available from Clontech), transforms DH5 α, bacterium forms the cDNA library.Measure the sequence of all clones' 5 ＇ and 3 ＇ ends with Dyeterminate cycle reaction sequencing kit (Perkin-Elmer company product) and ABI 377 automatic sequencers (Perkin-Elmer company).CDNA sequence and the existing public dna sequence data storehouse (Genebank) measured are compared, found that the cDNA sequence of one of them clone 0328B04 is new DNA.By synthetic a series of primers the contained insertion cDNA fragment of this clone is carried out two-way mensuration.The result shows, the contained full-length cDNA of 0328B04 clone is 1558bp (shown in Seq ID NO:1), from 20bp to 1198bp the open reading frame (ORF) of a 1178bp, the new protein (shown in Seq ID NO:2) of encoding arranged.We are with this clone's called after pBS-0328B04, and the name of encoded protein matter is people's congenital agyria protein 43.

Embodiment 2:cDNA clone's domain analyses

With the sequence and the encoded protein sequence thereof of people's congenital agyria protein 43 of the present invention, with profilescan program (Basiclocal Alignment search tool) [Altschul, the SF et al.J.Mol.Biol.1990 among the GCG; 215:403-10], carry out domain analyses at databases such as prosite.People's congenital agyria protein 43 of the present invention has homology at 180-228 and structural domain WD-40 tumor-necrosis factor glycoproteins, and homology the results are shown in Fig. 1, and homology is 0.10, must be divided into 4.92; Threshold value is 4.70.Embodiment 3: with the gene of RT-PCR method clones coding people congenital agyria protein 43

Total RNA is a template with fetus brain cell, is that primer carries out the synthetic cDNA of reverse transcription reaction with oligo-dT, with behind the test kit purifying of Qiagene, carries out pcr amplification with following primer:

Primer1：5?’-GGGTGGAGGCGGGGTCGAGATGGCG-3’(SEQ?ID?NO：3)

Primer2：5’-AACATATTTTCTTTATTTCCTCCAG-3’(SEQ?ID?NO：4)

Primer1 is the forward sequence that begins of 1bp that is positioned at the 5 ' end of SEQ ID NO:1;

Primer2 be SEQ ID NO:1 in 3 ' end reverse sequence.

The condition of amplified reaction: in the reaction volume of 50 μ 1, contain 50mmol/LKCl, 10mmol/L Tris-Cl, (pH8.5), 1.5mmol/L MgCl ₂, 200 μ mol/L dNTP, 10pmol primer, the Taq archaeal dna polymerase of 1U (Clontech company product).Go up by 25 cycles of following conditioned response at PE9600 type DNA thermal cycler (Perkin-Elmer company): 94 ℃ of 30sec; 55 ℃ of 30sec; 72 ℃ of 2min.When RT-PCR, establish the blank negative contrast of positive contrast of β-actin and template simultaneously.Amplified production is connected to (Invitrogen company product) on the pCR carrier with the test kit purifying of QIAGEN company with TA clone reagent gold.The dna sequence analysis result shows that the dna sequence dna of PCR product and the 1-1558bp shown in the SEQ ID NO:1 are identical.

Embodiment 4:Northern blotting analyst congenital agyria protein 43 expression of gene:

Extract total RNA[Anal.Biochem 1987,162,156-159 with single stage method].This method comprises acid guanidine thiocyanate phenol-chloroform extracting.Promptly use 4M guanidinium isothiocyanate-25mM Trisodium Citrate, 0.2M sodium acetate (pH4.0) carries out homogenate to tissue, adds the phenol of 1 times of volume and chloroform one primary isoamyl alcohol (49: 1) of 1/5 volume, and is centrifugal after mixing.The sucking-off aqueous phase layer adds Virahol (O.8 volume) and with the centrifugal RNA precipitation that obtains of mixture.With RNA precipitation 70% washing with alcohol that obtains, dry and soluble in water.With 20 μ g RNA, on 1.2% sepharose that contains 20mM 3-(N one morpholino) propanesulfonic acid (pH7.0)-5mML acid sodium-1mm EDTA-2.2M formaldehyde, carry out electrophoresis.Be transferred on the nitrocellulose filter then.With α- ³²P dATP prepares by random priming ³²The dna probe of P-mark.Used dna probe is people's congenital agyria protein 43 coding region sequence (20bp to 1198bp) of pcr amplification shown in Figure 1.Will ³²The probe of P-mark (about 2 * 10 ⁶Cpm/ml) spend the night in 420 ℃ of hybridization in a solution with the nitrocellulose filter that has shifted RNA, this solution comprises 50% methane amide-25mM KH ₂PO ₄(pH7.4)-5 * SSC-5 * Denhardt ' s solution and 200 μ g/ml salmon sperm DNAs.After the hybridization, filter membrane is washed 30min in 55 ℃ in 1 * SSC-0.1%SDS.Then, analyze with quantitative with Phosphor Imager.

Embodiment 5: vivoexpression, separation and the purifying of recombinant human congenital agyria protein 43

According to SEQ ID NO:1 and coding region sequence shown in Figure 1, design a pair of specificity amplification primer, sequence is as follows:

Primer3:5’-CCCGCTAGCATGGCGGCGCCTTTGAGGATTCAGA-3’(Seq?ID?No:5)

Primer4:5’-CCCAAGCTTGATAGAACTGGTGCTCCTGATCTGA-3’(Seq?ID?No:6)

5 ' end of these two sections primers contains Nde I and Hind III restriction enzyme site respectively, be respectively the encoding sequence of target gene 5 ' end and 3 ' end thereafter, Nde I and Hind III restriction enzyme site are corresponding to expression vector plasmid pET-28b (+) (Novagen company product, Cat.No.69865.3) the selectivity restriction enzyme site on.With the pBS-0328B04 plasmid that contains the total length goal gene is template, carries out the PCR reaction.The PCR reaction conditions is: contain pBS-0328B04 plasmid 10pg, primer Primer-3 and Primer-4 among the cumulative volume 50 μ l and be respectively 10pmol, Advantagepolymerase Mix (Clontech company product) 1 μ l.Loop parameter: 94 ℃ of 20s, 60 ℃ of 30s, 68 ℃ of 2min, totally 25 circulations.Respectively amplified production and plasmid pET-28 (+) are carried out double digestion with Nde I and Hind III, reclaim big fragment respectively, and connect with the T4 ligase enzyme.Connect product and transform, after the dull and stereotyped overnight incubation of the LB that contains kantlex (final concentration 30 μ g/ml), use the colony polymerase chain reaction (PCR) method screening positive clone, and check order with the big enterobacterial DH5 of Calcium Chloride Method α.Select the correct positive colony of sequence (pET-0328B04) with Calcium Chloride Method with recombinant plasmid transformed e. coli bl21 (DE3) plySs (Novagen company product).In the LB liquid nutrient medium that contains kantlex (final concentration 30 μ g/ml), host bacterium BL21 (pET-0328B04) is cultured to logarithmic phase at 37 ℃, adds IPTG to final concentration 1mmol/L, continues to cultivate 5 hours.Centrifugal collection thalline, through the broken bacterium of ultrasonic wave, centrifugal collection supernatant with carrying out chromatography with 6 Histidines (6His-Tag) bonded affinity column His.Bind Quick Cartridge (Novagen company product), has obtained the target protein people congenital agyria protein 43 of purifying.Through the SDS-PAGE electrophoresis, obtain a single band (Fig. 2) at the 43kDa place.This band is transferred on the pvdf membrane carries out the n terminal amino acid sequential analysis with the Edams hydrolysis method, 15 amino acid of N-end hold 15 amino-acid residues identical with the N-shown in the SEQ ID NO:2 as a result.

Embodiment 6 anti-people's congenital agyria protein 43 production of antibodies

Synthesize the specific polypeptide of following people's congenital agyria protein 43 with Peptide synthesizer (PE company product):

NH2-Met-Ala-Ala-Pro-Leu-Arg-Ile-Gln-Ser-Asp-Trp-Ala-Gln-Ala-Leu-COOH(SEQ?ID?NO:7)。Form compoundly with hemocyanin and bovine serum albumin coupling this polypeptide respectively, method is referring to Avrameas, et al.Immunochemistry, 1969; 6:43.Add the complete Freund's adjuvant immunizing rabbit with the above-mentioned hemocyanin polypeptide complex of 4mg, add the incomplete Freund's adjuvant booster immunization once with the hemocyanin polypeptide complex again after 15 days.Employing is done the titre that ELISA measures antibody in the rabbit anteserum through the titer plate of 15 μ g/ml bovine serum albumin polypeptide complex bag quilts.From the rabbit anteserum of antibody positive, separate total IgG with albumin A-Sepharose.Polypeptide is incorporated on the Sepharose4B post of cyanogen bromide-activated, from total IgG, separates anti-peptide antibody with affinity chromatography.Immuno-precipitation proof antibody purified can combine with people's congenital agyria protein 43 specifically.Embodiment 7: polynucleotide passage of the present invention is as the application of hybridization probe

Picking out suitable oligonucleotide fragment from polynucleotide of the present invention is of use in many ways as hybridization probe, as can whether containing polynucleotide sequence of the present invention and detect the homologous polynucleotide sequence to identify it with the healthy tissues of different sources or the genome or the hybridization of cDNA library of pathological tissue with this probe, whether further also available this probe in detecting polynucleotide sequence of the present invention or the expression of its homologous polynucleotide sequence in healthy tissues or pathological tissue cell be unusual.

The purpose of present embodiment is to pick out suitable oligonucleotide fragment as hybridization probe from polynucleotide SEQ ID NO:1 of the present invention, and identifies in some tissues whether contain polynucleotide sequence of the present invention or its homologous polynucleotide sequence with the filter hybridization method.The filter hybridization method comprises dot blotting, Southern blotting, Northern blotting and copy method etc., and they all are that polynucleotide sample to be measured is fixed on use essentially identical step crossover in back on the filter membrane.These identical steps are: the filter membrane of having fixed sample at first carries out prehybridization with the hybridization buffer that does not contain probe, so that nonspecific combining site suppressed by vector of sample and synthetic polymer institute are saturated on the filter membrane.Prehybridization solution is contained the hybridization buffer replacement of label probe then, and insulation makes probe and target nucleic acid hybridization.After the hybridization step, the probe in the hybridization is not removed by a series of film steps of washing.Present embodiment utilizes the film condition of washing (as than low salt concn and higher temperature) of higher-strength, so that hybrid context reduces and only keep the signal of high specificity.The probe that present embodiment is selected for use comprises two classes: first kind probe be fully with the identical or complementary oligonucleotide fragment of polynucleotide SEQ ID NO:1 of the present invention; The second class probe is part and the identical or complementary oligonucleotide fragment of polynucleotide SEQ ID NO:1 of the present invention.Present embodiment selects for use dot blotting that sample is fixed on the filter membrane, higher-strength wash under the film condition, the hybridization specificity of first kind probe and sample is the strongest and kept.

One, probe selects for use

From polynucleotide SEQ ID NO:1 of the present invention, select oligonucleotide fragment as hybridization probe, the several aspects that should follow following principle and need to consider: 1, the probe size preferable range is a 18-50 Nucleotide; 2, GC content is 30%-70%, and surpassing then, non-specific hybridization increases; 3, probe interior should not have complementary region; 4, what meet above condition can be used as the primary election probe, further do the computer sequential analysis then, comprise this primary election probe is carried out homology relatively with its source sequence area (being SEQ ID NO:1) and other known genome sequence and complementary district thereof respectively, if with the homology in non-target molecule zone greater than 85% or there are 15 continuous bases of surpassing identical, then this primary election probe is general just should not use; 5, whether the primary election probe finally is chosen to be the probe of actual application value also should further be determined by experiment.

Select and synthetic following two probes after finishing the analysis of above each side:

Probe 1 (probe1) belongs to first kind probe, with complete homology of gene fragment or the complementation (41Nt) of SEQ ID NO:1

5’-CCTCAGGAAGGATGAAGGGGAGGCCTGGCTGAGCTGTCATC-3’ (SEQ?I?D?NO:8)

Probe 2 (probe2) belongs to the second class probe, is equivalent to gene fragment or its complementary segmental replacement mutant nucleotide sequence (41Nt) of SEQ ID NO:1:

5’-CGTGAGAAATGAAGATGGTGATGCCTTGCCTAAGTTGCCAC-3’ (SEQ?ID?NO:9)

Other unlisted common agents and the compound method thereof relevant with following concrete experimental procedure please refer to document: DNA PROBES G.H.Keller; M.M.Manak; Stockton Press, 1989 (USA) and molecular cloning laboratory manual books more commonly used are as works such as " molecular cloning experiment guide " (second edition in 1998) [U.S.] Sa nurse Brooker, Science Press.

Specimen preparation: 1, from fresh or frozen tissue, extract DNA

Step: 1) the fresh or fresh normal liver tissue that thaws is put into the plate that is immersed on ice and fills phosphate buffered saline buffer (PBS).With scissors or scalpel tissue is cut into small pieces.Should keep organizing moistening in the operation.2) with 1000g centrifugal chopper tissue 10 minutes.3) with cooled homogenate damping fluid (0.25mol/L sucrose; 25mmol/LTris-HCl, pH7.5; 25mmol/LnaCl; 25mmol/L MgCl ₂) precipitation that suspends (approximately 10ml/g).4) 4 ℃ with electric homogenizer homogenate tissue suspension at full speed, until tissue by broken fully.5) 1000g is centrifugal 10 minutes.6) with re-suspended cell precipitation (the initial tissue sample of every 0.1g adds 1-5ml), centrifugal 10 minutes again with 1000g.7) with the resuspended precipitation of lysis buffer (the initial tissue sample of every 0.1g adds 1ml), connect following phenol extraction process then.2, the phenol extraction process of DNA

Step: 1) wash cell, centrifugal 10 minutes of 1000g with the cold PBS of 1-10ml.2) with the sedimentary cell (1 * 10 of cold cell pyrolysis liquid resuspension ⁸The minimum of applications 100ul lysis buffer of cell/ml).3) adding SDS is 1% to final concentration, if before re-suspended cell SDS is directly joined in the cell precipitation, cell may form big agglomerate and be difficult to fragmentation, and the overall yield that reduces.This point is in extracting＞10 ⁷Especially severe during cell.4) add Proteinase K to final concentration 200ug/ml.5) 50 ℃ of insulation reaction 1 hour or 37 ℃ gently jolting spend the night.6) use equal-volume phenol: chloroform: primary isoamyl alcohol (25: 24: 1) extracting, in little centrifuge tube centrifugal 10 minutes.Two corresponding clear separation, otherwise carry out centrifugal again.7) water is transferred to new pipe.8) use the equal-volume chloroform: primary isoamyl alcohol (24: 1) extracting, centrifugal 10 minutes.9) water that will contain DNA is transferred to new pipe.Carry out purifying and the ethanol sedimentation of DNA then.3, the purifying of DNA and ethanol sedimentation

Step: 1) 1/10 volume 2mol/L sodium-acetate and 2 times of cold 100% ethanol of volume are added in the dna solution mixing.-20 ℃ of placements 1 hour or to spending the night.2) centrifugal 10 minutes.3) careful sucking-off or pour out ethanol.4) with 70% cold ethanol 500ul washing precipitation, centrifugal 5 minutes.5) careful sucking-off or pour out ethanol.With the cold washing with alcohol precipitation of 500ul, centrifugal 5 minutes.6) careful sucking-off or pour out ethanol is inverted on thieving paper then residual ethanol is flow to end.Dry air 10-15 minute, so that the volatilization of surperficial ethanol.Note not making the precipitation complete drying, otherwise dissolve again than difficulty.7) with small volume TE or the resuspended DNA precipitation of water.The low speed vortex vibrates or uses the dropper pressure-vaccum, increases TE gradually simultaneously, is mixed to DNA and fully dissolves, every 1-5 * 10 ⁶Cell extracted approximately adds 1ul.

Below the 8-13 step only be used for must removing when depolluting, otherwise can directly carry out the 14th step.8) RNA enzyme A is added in the dna solution, final concentration is 100ug/ml, and 37 ℃ are incubated 30 minutes.9) add SDS and Proteinase K, final concentration is respectively 0.5% and 100ug/ml.37 ℃ are incubated 30 minutes.10) use isopyknic phenol: chloroform: primary isoamyl alcohol (25: 24: 1) extractive reaction liquid, centrifugal 10 minutes.11) carefully shift out water, use isopyknic chloroform: primary isoamyl alcohol (24: 1) extracting again, centrifugal 10 minutes.12) carefully shift out water, add 1/10 volume 2mol/L sodium-acetate and the cold ethanol of 2.5 volumes, mixing put-20 ℃ 1 hour.13) with 70% ethanol and 100% washing with alcohol precipitation, dry air, resuspended nucleic acid, process is with the 3-6 step.14) measure A ₂₆₀And A ₂₈₀To detect purity and the productive rate of DNA.15) deposit in-20 ℃ after the packing.The preparation of sample film:

1) get 4 * 2 suitably nitrocellulose filters (NC film) of size, mark point sample position and sample number thereon gently with pencil, each probe needs two NC films, so that wash film with high strength condition and strength condition respectively in the experimental procedure of back.

2) draw and contrast respectively 15 microlitres, put on the sample film, dry at room temperature.

3) place infiltration that 0.1mol/LNaOH is arranged, last 5 minute of filter paper (twice) of 1.5mol/LNaCl, drying to place to soak into has 0.5mol/L Tris-HCl (pH7.0), last 5 minute of filter paper (twice) of 3mol/LNaCl, dries.

4) be sandwiched in the clean filter paper, wrap, 60-80 ℃ of vacuum-drying 2 hours with aluminium foil.

The mark of probe

1) 3 μ lProbe (0.10D/10 μ l) add 2 μ lKinase damping fluids, 8-10uCi γ- ³²P-dATP+2UKinase is to add to final volume 20 μ l.

2) 37 ℃ are incubated 2 hours.

3) add the tetrabromophenol sulfonphthalein indicator (BPB) of 1/5 volume.

4) cross Sephadex G-50 post.

5) to having ³²Before washing out, P-Probe begins to collect first peak (available Monitor monitoring).

6) 5/pipe, collect the 10-15 pipe.

7) monitor isotopic weight with liquid glimmer instrument

8) merge and to be required preparation behind the collection liquid of first peak ³²P-Probe (second peak for free γ- ³²P-dATP).

Prehybridization

The sample film is placed plastics bag, and adding 3-10mg prehybridization solution (10 * Denhardt ' s; 6 * SSC, 0.1mg/mlCT DNA (calf thymus DNA).), seal sack after, 68 ℃ of water-baths were shaken 2 hours.

Hybridization

Plastics bag is cut off one jiao, adds the probe prepare, seal sack after, 42 ℃ of water-baths are shaken and are spent the night.

Wash film: high strength is washed film:

1) good sample film has been hybridized in taking-up.

2) 2 * SSC among the 0.1%SDS, washes 15 minutes (2 times) for 40 ℃.

3) 0.1 * SSC among the 0.1%SDS, washes 15 minutes (2 times) for 40 ℃.

4) 0.1 * SSC among the 0.1%SDS, washes 30 minutes (2 times) for 55 ℃, and room temperature is dried.Low strength is washed film:

1) good sample film has been hybridized in taking-up.

2) 2 * SSC among the 0.1%SDS, washes 15 minutes (2 times) for 37 ℃.

3) 0.1 * SSC among the 0.1%SDS, washes 15 minutes (2 times) for 37 ℃.

4) 0.1 * SSC among the 0.1%SDS, washes 15 minutes (2 times) for 40 ℃, and room temperature is dried.

X-light autography:

-70 ℃, X-light autography (the compressing tablet time decides according to hybridization spot radioactivity is strong and weak).

Experimental result:

Adopt low strength to wash the hybrid experiment that the film condition is carried out, more than two strong and weak not obviously differences of probe hybridization spot radioactivity; And adopting high strength to wash the hybrid experiment that the film condition is carried out, the hybridization spot radioactive intensity of probe 1 obviously is better than the radioactive intensity of another probe hybridization spot.Thereby available probe 1 is qualitative and analyze existence and the differential expression of polynucleotide of the present invention in different tissues quantitatively.

Embodiment 8 DNA Microarray

Gene chip or gene micromatrix (DNA Microarray) are that present many National Laboratories and big drugmaker are all in the new technology of setting about developing and developing, it is meant and is arranged in a large amount of target fragments on the carriers such as glass, silicon in an orderly manner, to high-density, carry out the comparison and the analysis of data then with fluoroscopic examination and computer software, to reach purpose quick, efficient, that bioinformation is analyzed on high-throughput ground.Polynucleotide of the present invention can be used as target DNA and are used for biochip technology and are used for high-throughput and study new gene function; Seek and the new gene of the screening tissue specificity new gene of disease-related such as tumour particularly; The diagnosis of disease is as heredopathia.The existing in the literature multiple report of its concrete grammar step is as consulting document DeRisi, J.L., Lyer, V.﹠amp; Brown, P.O. (1997) Science278,680-686. and document Helle, R.A., Schema, M., Chai, A., Shalom, D., (1997) PNAS 94:2150-2155.

(1) point sample

Various full-length cDNA amounts to 4000 polynucleotide sequences as target DNA, comprising polynucleotide of the present invention.They are increased by PCR respectively, behind the purifying gained amplified production its concentration is transferred to about 500ng/ul, (available from U.S. Cartesian company) puts on glass medium with Cartesian 7500 point sample instruments, and distance between points is 280 μ m.Slide behind the point sample is carried out hydration, drying, places UV-crosslinked instrument crosslinked, and the wash-out after drying is fixed on DNA and is prepared into chip on the sheet glass.The existing in the literature multiple report of its concrete grammar step, the point sample post-processing step of present embodiment is:

1. hydration 4 hours in the wet environment;

2. the 0.2%SDS washing is 1 minute;

3. ddH ₂The O washed twice, each 1 minute;

4. NaBH ₄Sealed 5 minutes;

5. in 95 ℃ of water 2 minutes;

6. the 0.2%SDS washing is 1 minute;

7. ddH ₂Twice of O flushing;

8. airing, 25 ℃ to be stored in the dark place standby.

(2) probe mark

With the single stage method total mRNA of extracting from normal hepatocytes and liver cancer respectively, and with Oligotex mRNA Midi Kit (available from QiaGen company) purified mRNA, by reverse transcription respectively with fluorescent reagent Cy3dUTP (5-Amino-propargyl-2'-deoxyuridine 5 '-triphate coupled to Cy3 fluorescent dye, available from Amersham Phamacia Biotech company) mRNA of mark normal liver tissue, with fluorescent reagent Cy5dUTP (5-Amino-propargyl-2 '-deoxyuridine 5 '-triphate coupled to Cy5fluorescent dye, available from Amersham Phamacia Biotech company) the labelling liver cancer tissue mRNA, prepare probe after purified.Concrete steps reference and method Schena, M., Shalon, D., Heller, R. (1996) Proc.Natl.Acad.Sci.USA.Vol.93:10614-10619.Schena, M., Shalon, Dari., Davis, R.W. (1995) Science.270. (20): 467-480.

(3) hybridization

Respectively will be from the probe of above two kinds of tissues with chip at UniHyb ^TMHybridized 16 hours in HybridizationSolution (available from the TeleChem company) hybridization solution, room temperature washings (1 * SSC, 0.2%SDS) the washing back is scanned with ScanArray 3000 scanners (available from U.S. General Scanning company), the image of scanning carries out data analysis with Imagene software (U.S. Biodiscovery company) to be handled, calculate the Cy3/Cy5 ratio of each point, this ratio is considered to express discrepant gene less than 0.5 greater than 2 point.Experimental result shows, Cy3 signal=4328.7 (getting the mean value of four experiments), Cy5signal=5231.05 (getting the mean value of four experiments), Cy3/Cy5=0.8275012, the expression of polynucleotide of the present invention in above two kinds of tissues do not have notable difference, shows that polynucleotide of the present invention and liver cancer are irrelevant.

Sequence table (1) general information: (ⅱ) denomination of invention: people's congenital agyria protein 43 and encoding sequence thereof (ⅲ) sequence number: the information of 9 (2) SEQ ID NO:1: (ⅰ) sequence signature:

(A) length: 1558bp

(B) type: nucleic acid

(C) chain: two strands

( D ) ： ( ⅱ ) ：cDNA ( ⅹⅰ ) ：SEQ ID NO:1: 1 GGGTGGAGGCGGGGTCGAGATGGCGGCGCCTTTGAGGATTCAGAGCGACTGGGCGCAAGC 61 CCTCAGGAAGGATGAAGGGGAGGCCTGGCTGAGCTGTCATCCCCCAGGGAAACCATCTTT121 GTATGGTAGCCTGACTTGTCAAGGAATTGGCCTAGATGGCATCCCAGAGGTTACAGCTTC181 AGAAGGATTTACTGTGAATGAAATAAACAAGAAAAGCATTCATATTTCATGTCCAAAGGA241 AAATGCATCTTCTAAGTTTTTGGCACCATATACTACTTTTTCCGGAATTCATACAAAGAG301 TATAACATGCCTGGACATTTCCAGCAGAGGAGGTCTTGGTGTGTCTTCTAGTACTGACGG361 GACCATGAAAATCTGGCAGGCTTCCAATGGAGAACTCAGGAGAGTATTGGAAGGACATGT421 GTTTGATGTGAATTGTTGCAGGTTTTTCCCATCAGGCCTTGTGGTCCTGAGTGGGGGAAT481 GGATGCCCAGCTGAAGATATGGTCAGCTGAAGATGCTAGCTGCGTGGTGACCTTCAAAGG541 TCACAAAGGAGGTATCCTGGATACAGCCATCGTTGATCGGGGGAGGAATGTGGTGTCTGC601 TTCTCGAGATGGGACAGCACGACTTTGGGATTGTGGGCGCTCAGCCTGCTTGGGGGTCCT661 TGCAGATTGTGGTTCTTCTATCAATGGAGTGGCGGTGGGTGCTGCTGACAACTCCATAAA721 CCTTGGCTCCCCTGAGCAGATGCCCAGTGAACGGGAGGTTGGAACAGAGGCCAAAATGCT781 GCTCTTGGCCCGGGAAGATAAGAAACTTCAGTGCTTGGGACTACAGAGCAGGCAGCTGGT841 GTTCCTCTTTATTGGCTCAGACGCTTTCAACTGCTGTACTTTTCTCTCTGGCTTCTTGCT901 ATTGGCTGGGACTCAAGATGGAAACATTTATCAGCTGGATGTGAGGAGTCCAAGGGCTCC 961 GGTACAAGTCATCCACAGATCAGGAGCACCAGTTCTATCCCTGCTAAGTGTCAGAGATGG1021 ATTCATTGCTAGCCAAGGTGATGGAAGCTGTTTTATTGTCCAGCAAGACTTAGACTATGT1081 CACTGAGCTCACTGGGGCTGACTGTGACCCTGTGTACAGGGTAGCCACATGGGAGAAGCA1141 GATCTACACATGCTGTCGAGACGGTCTTGTACGACGCTACCAGCTTTCTGACCTCTGACT1201 TCTTGGAAAGAGCAGTCCCGGTTAGTGAAAAGGTTTGACCCTGATCAACAATGAGCAGAA1261 ACATCATCAGTCCTTCCCAAGGACCATGGCGTTTAATGTCTTGGGCACCCCTTGGAAATC1321 ACAGAAAGTCAGCTGTACTGGCCGTGTGGAACTCTCATCCCAAGACCTACTTTGAACTGA1381 GTAAGAAGGTCATTGTGCCCACTGCATTTGTTCCAACTTCTCCTTGTATAAACTCACCCC1441 AGCAACACAGGGCAAGGATATAGATGCTTTTAGTTTGTTCTTAAACCAGTTTTGTTAAAT1501 GTTTACAAGGACCTCAGTACTAAAGCCTGTTCTCTGGAGGAAATAAAGAAAATATGTT ( 3 ) SEQ ID NO:2： ( ⅰ ) ：

(A) length: 416 amino acid

(B) type: amino acid

( D ) ： ( ⅱ ) ： ( ⅹⅰ ) ：SEQ ID NO:2: 1 Met Ala Ala Pro Leu Arg Ile Gln Ser Asp Trp Ala Gln Ala Leu 16 Arg Lys Asp Glu Gly Glu Ala Trp Leu Ser Cys His Pro Pro Gly 31 Lys Pro Ser Leu Tyr Gly Ser Leu Thr Cys Gln Gly Ile Gly Leu 46 Asp Gly Ile Pro Glu Val Thr Ala Ser Glu Gly Phe Thr Val Asn 61 Glu Ile Asn Lys Lys Ser Ile His Ile Ser Cys Pro Lys Glu Asn 76 Ala Ser Ser Lys Phe Leu Ala Pro Tyr Thr Thr Phe Ser Gly Ile 91 His Thr Lys Ser Ile Thr Cys Leu Asp Ile Ser Ser Arg Gly Gly106 Leu Gly Val Ser Ser Ser Thr Asp Gly Thr Met Lys Ile Trp Gln121 Ala Ser Asn Gly Glu Leu Arg Arg Val Leu Glu Gly His Val Phe136 Asp Val Ash Cys Cys Arg Phe Phe Pro Ser Gly Leu Val Val Leu151 Ser Gly Gly Met Asp Ala Gln Leu Lys Ile Trp Ser Ala Glu Asp166 Ala Ser Cys Val Val Thr Phe Lys Gly His Lys Gly Gly Ile Leu181 Asp Thr Ala Ile Val Asp Arg Gly Arg Asn Val Val Ser Ala Ser196 Arg Asp Gly Thr Ala Arg Leu Trp Asp Cys Gly Arg Ser Ala Cys211 Leu Gly Val Leu Ala Asp Cys Gly Ser Ser Ile Ash Gly Val Ala226 Val Gly Ala Ala Asp Asn Ser lle Asn Leu Gly Ser Pro Glu Gln241 Met Pro Ser Glu Arg Glu Val Gly Thr Glu Ala Lys Met Leu Leu256 Leu Ala Arg Glu Asp Lys Lys Leu Gln Cys Leu Gly Leu Gln Ser271 Arg Gln Leu Val Phe Leu Phe lle Gly Ser Asp Ala Phe Asn Cys296 Cys Thr Phe Leu Ser Gly Phe Leu Leu Leu Ala Gly Thr Gln Asp301 Gly Asn Ile Tyr Gln Leu Asp Val Arg Ser Pro Arg Ala Pro Val316 Gln Val Ile His Arg Ser Gly Ala Pro Val Leu Ser Leu Leu Ser331 Val Arg Asp Gly Phe Ile Ala Ser Gln Gly Asp Gly Ser Cys Phe346 Ile Val Gln Gln Asp Leu Asp Tyr Val Thr Glu Leu Thr Gly Ala361 Asp Cys Asp Pro Val Tyr Arg Val Ala Thr Trp Glu Lys Gln Ile376 Tyr Thr Cys Cys Arg Asp Gly Leu Val Arg Arg Tyr Gln Leu Ser391 Asp Leu ( 4 ) SEQ ID NO:3 ( ⅰ )

(A) length: 24 bases

(B) type: nucleic acid

(C) chain: strand

(D) topological framework: linear (ⅱ) molecule type: oligonucleotide (ⅹ ⅰ) sequence description: information (ⅰ) sequence signature of SEQ ID NO:3:GGGTGGAGGCGGGGTCGAGATGGCG 24 (5) SEQ ID NO:4

(A) length: 24 bases

(B) type: nucleic acid

(C) chain: strand

(D) topological framework: linear (ⅱ) molecule type: oligonucleotide (ⅹ ⅰ) sequence description: the information of SEQ ID NO:4:AACATATTTTCTTTATTTCCTCCAG 24 (6) SEQ ID NO:5

(ⅰ) sequence signature

(A) length: 34 bases

(B) type: nucleic acid

(C) chain: strand

(D) topological framework: linearity

(ⅱ) molecule type: oligonucleotide (ⅹ ⅰ) sequence description: the information of SEQ ID NO:5:CCCGCTAGCATGGCGGCGCCTTTGAGGATTCAGA 34 (7) SEQ ID NO:6

(ⅰ) sequence signature

(A) length: 34 bases

(B) type: nucleic acid

(C) chain: strand

(D) topological framework: linearity

(ⅱ) molecule type: oligonucleotide (ⅹ ⅰ) sequence description: the information of SEQ ID NO:6:CCCAAGCTTGATAGAACTGGTGCTCCTGATCTGA 34 (8) SEQ ID NO:7:

(ⅰ) sequence signature:

(A) length: 15 amino acid

(B) type: amino acid

(D) topological framework: linearity

(ⅱ) molecule type: polypeptide (ⅹ ⅰ) sequence description: information (ⅰ) sequence signature of SEQ ID NO:7:Met-Ala-Ala-Pro-Leu-Arg-Ile-Gln-Ser-Asp-Trp-Ala-Gln-Ala-Leu 15 (9) SEQ ID NO:8

(A) length: 41 bases

(B) type: nucleic acid

(C) chain: strand

(D) topological framework: linear (ⅱ) molecule type: oligonucleotide (ⅹ ⅰ) sequence description: information (ⅰ) sequence signature of SEQ ID NO:8:CCTCAGGAAGGATGAAGGGGAGGCCTGGCTGAGCTGTCATC 41 (10) SEQ ID NO:9

(A) length: 41 bases

(B) type: nucleic acid

(C) chain: strand

(D) topological framework: linear (ⅱ) molecule type: oligonucleotide (ⅹ ⅰ) sequence description: SEQ ID NO:9:CGTGAGAAATGAAGATGGTGATGCCTTGCCTAAGTTGCCAC 41

Claims (18)

1. An isolated polypeptide-human lissencephalic protein 43, characterized in that it comprises: a polypeptide of the amino acid sequence shown in SEQ ID NO: 2, or an active fragment, analog or derivative thereof. 2. The polypeptide according to claim 1, characterized in that the amino acid sequence of said polypeptide, analog or derivative has at least 95% identity with the amino acid sequence shown in SEQ ID NO:2. 3. The polypeptide according to claim 2, characterized in that it comprises a polypeptide having the amino acid sequence shown in SEQ ID NO:2. 4. An isolated polynucleotide, characterized in that said polynucleotide comprises one selected from the group consisting of: (a) a polynucleotide encoding a polypeptide having an amino acid sequence shown in SEQ ID NO: 2 or a fragment, analog, or derivative thereof; (b) a polynucleotide complementary to polynucleotide (a); or (c) A polynucleotide having at least 70% identity to (a) or (b). 5. The polynucleotide according to claim 4, characterized in that said polynucleotide comprises a polynucleotide encoding the amino acid sequence shown in SEQ ID NO:2. 6. The polynucleotide according to claim 4, wherein the sequence of the polynucleotide comprises the sequence of positions {20-1198} in SEQ ID NO:1 or positions 1-1558 in SEQ ID NO:1 the sequence of. 7. A recombinant vector containing an exogenous polynucleotide, characterized in that it is a recombinant vector constructed from the polynucleotide of any one of claims 4-6 and a plasmid, virus or carrier expression vector carrier. 8. A genetically engineered host cell containing an exogenous polynucleotide, characterized in that it is selected from the following host cells: (a) a host cell transformed or transduced with the recombinant vector according to claim 7; or (b) A host cell transformed or transduced with the polynucleotide according to any one of claims 4-6. 9. A method for preparing a polypeptide having human lissencephalic protein 43 activity, characterized in that the method comprises: (a) cultivating the engineered host cell according to claim 8 under the condition of expressing human lissencephaly protein 43; (b) isolating a polypeptide having human lissencephaly protein 43 activity from the culture. 10. An antibody capable of binding to a polypeptide, characterized in that the antibody is capable of specifically binding to human lissencephalic protein 43. 11. A class of compounds that mimic or modulate the activity or expression of polypeptides, characterized in that they are compounds that mimic, promote, antagonize or inhibit the activity of human lissencephalic protein 43. 12. The compound according to claim 11, characterized in that it is the antisense sequence of the polynucleotide sequence shown in SEQ ID NO: 1 or a fragment thereof. 13. A use of the compound as claimed in claim 11, characterized in that the compound is used for regulating the activity of human lissencephalic protein 43 in vivo and in vitro. 14. A method for detecting a disease or susceptibility to a disease associated with the polypeptide according to any one of claims 1-3, characterized in that it comprises detecting the expression level of the polypeptide, or detecting the activity of the polypeptide , or detect the nucleotide variation in the polynucleotide that causes abnormal expression or activity of the polypeptide. 15. The use of the polypeptide according to any one of claims 1-3, characterized in that it is used to screen for mimics, agonists, antagonists or inhibitors of human lissencephaly protein 43; or for use in Peptide fingerprinting identification. 16. The application of the nucleic acid molecule according to any one of claims 4-6, characterized in that it is used as a primer for nucleic acid amplification reactions, or as a probe for hybridization reactions, or for making gene chips or microarray. 17. The application of the polypeptide, polynucleotide or compound according to any one of claims 1-6 and 11, characterized in that the polypeptide, polynucleotide or its mimetic, agonist, antagonist Or the safe and effective dose of the inhibitor and a pharmaceutically acceptable carrier can be used as a pharmaceutical composition for diagnosing or treating diseases related to the abnormality of human lissencephaly protein 43. 18. The application of the polypeptide, polynucleotide or compound according to any one of claims 1-6 and 11, characterized in that the polypeptide, polynucleotide or compound is used to prepare for the treatment of malignant tumors, blood HIV infection and immune diseases and various types of inflammation drugs.

Images